Not All Japanese Companies Bothered By New Pharma Sales Law
This article was originally published in PharmAsia News
Executive SummaryJapan's June 1 effective date for its Pharmaceutical Affairs Law has presented a mixed bag for the drug industry, patients and a variety of new entrants into the business of selling medicines. Although the new law expanding some over-the-counter sales to convenience stores and shutting down a lot of online sales has claimed winners and losers, Daigen Pharmaceutical is experiencing a 50 percent increase in orders for its online products, such as an athlete's foot treatment. Daigen is benefiting, however, from a two-year window allowing continued online sales of drugs to people who already had been buying them before June 1. (Click here for more - a subscription may be required
You may also be interested in...
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).
CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.